Dutch consumer electronics giant Philips Electronics NV (PHGFF.PK, PHG) reported Monday that its fourth-quarter income from operations was 24 million euros, including charges of 363 million euros connected with the Respironics consent decree, which has been agreed with the US Department of Justice or DOJ, representing the US Food and Drug Administration.
Adjusted EBITA margin was 12.9 percent in the quarter. Adjusted EBITA margin was 12.5 percent, excluding provisions charged to sales, mainly connected with the Respironics consent decree.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com